A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The standard treatment for PTCL is CHOP (cyclophosphamide (C), adriamycin (H), vincristine
(O), and prednisone (P)) chemotherapy. This study is attempting to determine whether adding
other treatments to CHOP therapy will improve the chance of the disease going into remission
or staying in remission. Because other drugs for T-cell lymphoma have not yet been given with
CHOP, this study is looking at combining CHOP with ONTAK. ONTAK has been FDA approved for
treatment of Cutaneous T cell Lymphoma and works by specifically binding to a protein on the
surface of the tumor cells and killing the cell without causing damage to other types of
cells in the body. Studies have shown that ONTAK has helped patients with PTCL who have
failed chemotherapy.